Roche also shared the design of its upcoming Phase III TRONTIER 1 and 2 trials investigating trontinemab in people with early symptomatic Alzheimer’s disease
The PATHWAY HER2 (4B5) test, the first and only FDA approved companion diagnostic for assessing HER2-low status since 2022, is now also approved to aid in the assessment of HER2-ultralow status for metastatic breast cancer patients.
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results
Roche confirms that its cobas MPXV test, as well as the LightMix research use only kits, detect the latest mpox virus variants
The acquisition of LumiraDx’s Point of Care technology received all required antitrust and regulatory clearances
The built-in AI-trained algorithms will empower users to proactively intervene when their glucose levels require attention and before a complication can even occur
This clearance is a foundational step in Roche's commitment to enable routine clinical diagnosis with its digital pathology solutions
Approximately half of all patients with metastatic breast cancer (mBC) express low levels of HER2
The new tests can support clinical decision making when prescribing direct oral anticoagulants for stroke prevention
Roche will pay a purchase price of USD 295 million and an additional payment of up to USD 55 million
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
